Literature DB >> 28316019

Population pharmacokinetic analysis of rebamipide in healthy Korean subjects with the characterization of atypical complex absorption kinetics.

Lien Ngo1, Hee-Doo Yoo1, Phuong Tran1, Hea-Young Cho2, Yong-Bok Lee3.   

Abstract

In this study, the population pharmacokinetic (PK) analysis of rebamipide (Reba) in healthy male Korean subjects was analyzed using the nonlinear mixed effects modeling method. The possible effects of physiological covariates and the multidrug resistance (MDR1) gene 3435C>T polymorphism on PK parameters were also investigated. Data were collected from a bioequivalence study, in which 26 subjects who participated in the study were administered a single oral dose of 100 mg Reba; only data from the reference formulation were used. Reba showed a relatively large inter-individual variability (from 2.6- to 3.3-fold) in the PK parameters with double peaks or the concentration plateau after the peak concentration in its serum concentration-time profiles. The population PKs of Reba was best described by a one-compartment model with three fraction absorption processes followed a single Weibull-type function and two first-order kinetics, and lag times. The study suggests that the efflux transporter MDR1 3435C>T allele affects the substantial inter-individual variability in the absorption of Reba according to genetic polymorphism. A significant difference was found in the absorption rate ka 1 among the MDR1 3435C>T genotype groups (P < 0.05) (CT group, 79.8% increase; and TT group, 115% increase). The use of combined MDR1 3435C>T and body mass index as covariates for ka 1 exerted a more significant effect (P < 0.05). In addition, body surface area significantly affected the apparent total clearance (P < 0.05).

Entities:  

Keywords:  Genetic polymorphism; MDR1; Pharmacokinetics; Population; Rebamipide

Mesh:

Substances:

Year:  2017        PMID: 28316019     DOI: 10.1007/s10928-017-9519-z

Source DB:  PubMed          Journal:  J Pharmacokinet Pharmacodyn        ISSN: 1567-567X            Impact factor:   2.745


  55 in total

1.  Population pharmacokinetic analysis of simvastatin and its active metabolite with the characterization of atypical complex absorption kinetics.

Authors:  Seok-Joon Jin; Kyun-Seop Bae; Sang-Heon Cho; Jin-Ah Jung; Unjib Kim; Sangmin Choe; Jong-Lyul Ghim; Yook-Hwan Noh; Hyun-Jung Park; Hee-Sun Kim; Hyeong-Seok Lim
Journal:  Pharm Res       Date:  2014-02-19       Impact factor: 4.200

2.  Formulation of solid dispersion of rebamipide evaluated in a rat model for improved bioavailability and efficacy.

Authors:  Nguyen-Thach Tung; Chun-Woong Park; Tack-oon Oh; Ju-Young Kim; Jung-Myung Ha; Yun-Seok Rhee; Eun-Seok Park
Journal:  J Pharm Pharmacol       Date:  2011-12       Impact factor: 3.765

3.  Rebamipide protects against activation of neutrophils by Helicobacter pylori.

Authors:  N Yoshida; T Yoshikawa; S Iinuma; M Arai; S Takenaka; K Sakamoto; T Miyajima; Y Nakamura; N Yagi; Y Naito; F Mukai; M Kondo
Journal:  Dig Dis Sci       Date:  1996-06       Impact factor: 3.199

4.  The predictive value of MDR1, CYP2C9, and CYP2C19 polymorphisms for phenytoin plasma levels.

Authors:  R Kerb; A S Aynacioglu; J Brockmöller; R Schlagenhaufer; S Bauer; T Szekeres; A Hamwi; M Fritzer-Szekeres; C Baumgartner; H Z Ongen; P Güzelbey; I Roots; U Brinkmann
Journal:  Pharmacogenomics J       Date:  2001       Impact factor: 3.550

Review 5.  Pharmacogenetics and human genetic polymorphisms.

Authors:  Ann K Daly
Journal:  Biochem J       Date:  2010-08-01       Impact factor: 3.857

6.  Pharmacokinetic compartmental model with n sites of absorption along the gastrointestinal tract.

Authors:  Y Plusquellec; G Houin
Journal:  Arzneimittelforschung       Date:  1994-05

7.  Kinetics of acetaminophen absorption and gastric emptying in man.

Authors:  J A Clements; R C Heading; W S Nimmo; L F Prescott
Journal:  Clin Pharmacol Ther       Date:  1978-10       Impact factor: 6.875

8.  Mechanism of hydroxyl radical scavenging by rebamipide: identification of mono-hydroxylated rebamipide as a major reaction product.

Authors:  Kazushi Sakurai; Hiroyuki Sasabe; Toshihisa Koga; Tetsuya Konishi
Journal:  Free Radic Res       Date:  2004-05

9.  Development of a rebamipide solid dispersion system with improved dissolution and oral bioavailability.

Authors:  Roshan Pradhan; Tuan Hiep Tran; Ju Yeon Choi; Im Soon Choi; Han-Gon Choi; Chul Soon Yong; Jong Oh Kim
Journal:  Arch Pharm Res       Date:  2014-06-04       Impact factor: 4.946

10.  Antiulcer mechanism of action of rebamipide, a novel antiulcer compound, on diethyldithiocarbamate-induced antral gastric ulcers in rats.

Authors:  K Ogino; T Hobara; H Ishiyama; K Yamasaki; H Kobayashi; Y Izumi; S Oka
Journal:  Eur J Pharmacol       Date:  1992-02-25       Impact factor: 4.432

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.